Skip to main content
. Author manuscript; available in PMC: 2015 Mar 5.
Published in final edited form as: J Alzheimers Dis. 2012;28(4):783–794. doi: 10.3233/JAD-2011-111208

Fig. 6.

Fig. 6

Double immunolabeling studies for pE(3)Aβ and dendritic and synaptic markers co-localization in early and advanced AD. Co-localization studies were performed with the D129 antibody and the dendritic marker MAP2 or the synaptic marker synaptophysin in the frontal cortex of AD at varying stages of the disease. a–c) Co-localization between MAP2 and D129 immunoreactivity in the frontal cortex of a patient with early stage AD. d–f) Co-localization between MAP2 and D129 immunoreactivity in the frontal cortex of a patient with late AD. g–i) Co-localization between synaptophysin and D129 immunoreactivity in the frontal cortex of a patient with early stage AD. j–l) Co-localization between synaptophysin and D129 immunoreactivity in the frontal cortex of a patient with late stage AD. pl = plaque. Arrows indicate regions of co-localization. Scale bar = 30 µM.